Table 1.
Differences between groups of patients according to preserved residual renal function in a total of 76 patients enrolled in the study
| Patients with preserved RRF (n = 20), n (%), mean ± SD, or mean rank | Patients without preserved RRF (n = 56), n (%), mean ± SD, or mean rank | p value | |
|---|---|---|---|
| Sex, males/females | 9 (45%)/11 (55%) | 38 (68%)/18 (32%) | 0.07 |
| Age, years | 59.8 ± 13.4 | 64.1 ± 14.3 | 0.2 |
| Dialysis vintage, years | 37.92 | 38.71 | 0.9 |
| Kt/V for urea | 41.48 | 37.44 | 0.5 |
| nPCR, g/kg/day | 2.2 ± 0.5 | 2.4 ± 0.5 | 0.1 |
| Interdialytic urine volume, mL | 211 ± 143 | – | – |
| Body mass index | 24.5 ± 3.0 | 24.4 ± 3.1 | 0.9 |
| Interdialytic weight gain, kg | 2.1 ± 1.1 | 2.2 ± 0.9 | 0.8 |
| Intact parathormone, pg/mL | 36.82 | 43.20 | 0.3 |
| Calcium corrected for albumin, mg/dL | 9.5 ± 0.8 | 9.4 ± 0.6 | 0.5 |
| Phosphate, mg/dL | 5.3 ± 1.5 | 5.7 ± 2.1 | 0.3 |
| Calcium × phosphate product | 50.5 ± 17.4 | 54.1 ± 19.4 | 0.4 |
| Hemoglobin, g/dL | 11.9 ± 1.3 | 11.8 ± 1.3 | 0.8 |
| Albumin, g/dL | 40.2 | 37.9 | 0.7 |
| Low-density lipoprotein/high-density lipoprotein | 2.2 ± 0.8 | 2.3 ± 0.9 | 0.5 |
| Glucose, mg/dL | 93.9 ± 15.8 | 96.5 ± 28.3 | 0.6 |
| Insulin, µU/mL | 36.5 | 39.3 | 0.6 |
| HOMA-IR, mmol/L | 37.5 | 38.8 | 0.8 |
| Monocyte chemoattractant protein-1, pg/mL | 30.1* | 41.5 | 0.04 |
| High-sensitivity C-reactive protein, mg/L | 6.8 ± 4.7 | 8.4 ± 6.2 | 0.3 |
| Carotid-femoral pulse wave velocity, m/s | 11.2 ± 1.8 | 11.3 ± 1.9 | 0.9 |
| Augmentation index, % | 24.1 ± 2.08 | 24.4 ± 2.5 | 0.6 |
| Pulse pressure, mm Hg | 56.5 ± 18.6 | 62.9 ± 20.9 | 0.2 |
| Mean peripheral predialysis BP, mm Hg | 97.7 ± 12.5 | 100.5 ± 13.2 | 0.4 |
| Ankle-brachial index | 1.1 ± 0.3 | 1.1 ± 0.5 | 0.9 |
| Interventricular septum thickness, mm | 18.4* | 45.7 | 0.001 |
| EF, % | 42.7 | 37.01 | 0.3 |
| E/A ratio | 57.03* | 31.9 | 0.001 |
| Diabetics/nondiabetics | 1 (5%)/19 (95%) | 6 (10.7%)/50 (89.3%) | 0.3 |
| Smoking, yes/no | 6 (30%)/14 (70%) | 13 (23.2%)/43 (76.8%) | 0.8 |
| Left ventricular hypertrophy, yes/no | 7 (35%)/13 (65%)* | 39 (70%)/17 (30%) | 0.007 |
| Coronary artery disease, yes/no | 9 (45%)/11 (55%) | 16 (29%)/40 (71%) | 0.5 |
| Diastolic dysfunction, yes/no | 5 (25%)/15 (75%)* | 41 (73%)/15 (27%) | 0.001 |
| Systolic dysfunction (EF <50%), yes/no | 4 (20%)/16 (80%) | 18 (32%)/38 (68%) | 0.4 |
| Peripheral artery disease, yes/no | 12 (60%)/8 (40%)* | 19 (34%)/37 (66%) | 0.03 |
| Hypertension, yes/no | 10 (50%)/10 (50%) | 19 (34%)/37 (66%) | 0.6 |
BP, blood pressure; EF, ejection fraction; HOMA-IR, homeostatic model assessment of insulin resistance; nPCR, normalized protein catabolic rate for dry body mass; RRF, residual renal function; SD, standard deviation.
*
p < 0.05.